Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0173

Sigma-Aldrich

Reversan

≥98% (HPLC)

Synonym(s):

CBLC4H10, N-[3-(4-Morpholinyl)propyl]-5,7-diphenyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H27N5O2
CAS Number:
313397-13-6
Molecular Weight:
441.52
MDL number:
MFCD01528184
UNSPSC Code:
12161501
PubChem Substance ID:
329825203
NACRES:
NA.77
Pricing and availability is not currently available.

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

faintly yellow to yellow

solubility

DMSO: ≥8 mg/mL at ~60 °C

storage temp.

2-8°C

SMILES string

O=C(NCCCN1CCOCC1)c2cnn3c(cc(nc23)-c4ccccc4)-c5ccccc5

InChI

1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32)

InChI key

JTRXWCLQFAZHGP-UHFFFAOYSA-N

Application

Reversan may be used in cell signaling studies.

Biochem/physiol Actions

Nontoxic MRP1 function inhibitor; MRP1 and Pgp function inhibitor; multidrug transporter inhibitor
Reversan increases the efficacy of vincristine and etoposide and increases the sensitivity of murine models of neuroblastoma to conventional chemotherapy.[1][2]
Reversan is a selective and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp) inhibitor.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
101M4615V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Catherine A Burkhart et al.
Cancer research, 69(16), 6573-6580 (2009-08-06)
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine
Isabel Koh et al.
Communications biology, 7(1), 177-177 (2024-02-29)
With the advent of increasingly sophisticated organoids, there is growing demand for technology to replicate the interactions between multiple tissues or organs. This is challenging to achieve, however, due to the varying culture conditions of the different cell types that
Michelle J Henderson et al.
Journal of the National Cancer Institute, 103(16), 1236-1251 (2011-07-30)
Although the prognostic value of the ATP-binding cassette, subfamily C (ABCC) transporters in childhood neuroblastoma is usually attributed to their role in cytotoxic drug efflux, certain observations have suggested that these multidrug transporters might contribute to the malignant phenotype independent
Katharina Esser-Nobis et al.
Hepatology (Baltimore, Md.), 62(2), 397-408 (2015-04-14)
Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper
Frank Loganzo et al.
Molecular cancer therapeutics, 14(4), 952-963 (2015-02-04)
Antibody-drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service